ESMO 2025 – Datroway and Trodelvy face off in triple-negative breast
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
ESMO 2025 – Enhertu’s perioperative Destiny beckons
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
ESMO 2025 preview – Enhertu's early breast hat-trick
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
